ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 1435

Acute Effects of IL-6 Blockade, TNFα Inhibitor or Glucocorticoids on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis

Angelo Fassio1, GIovanni Adami 1, Ombretta Viapiana 1, Luca Idolazzi 1, Giovanni Orsolini 1, Alessandro Giollo 1, Davide Gatti 2 and Maurizio Rossini 1, 1University of Verona, Verona, Italy, 2Univerisity of Verona, Verona, Italy

Meeting: ACR/ARP Annual Meeting 2019

Keywords: Bone, Rheumatoid arthritis (RA), tocilizumab and glucocorticoids, WNT Signaling

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Treatments Poster II: Established Treatments

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Wnt signaling is an important regulator of bone remodeling and it is involved in the pathogenesis of focal and systemic bone loss in Rheumatoid Arthritis (RA) patients. The aim of the present study is to investigate the short-term effects of three different anti-inflammatory therapies on Wnt inhibitors and bone turnover markers (BTMs) in patients with early RA.

Methods: We performed a retrospective analysis of prospectively collected data. We enrolled women affected by early RA (< 12 months) according to 2010 ACR/EULAR criteria who started treatment with certolizumab pegol (200 mg SC weekly), tocilizumab (162 mg SC weekly) or methyl-predinsolone (8 mg daily). Women enrolled in the study were required to have positive RF and/or positive ACPA and active disease (DAS28 ≥2.6) despite stable treatment with subcutaneous methotrexate (10-15 mg/week) for at least 6 months. Clinical parameters and blood samples were collected at baseline, week 1 and week 4.

Results: Data were obtained for 14 patients treated with certolizumab pegol, 14 patients treated with tocilizumab and 20 patients treated with methyl-prednisolone. Mean DAS28 at baseline was 4.0 ± 0.7 No difference in any of the tested parameters was found at baseline. The percent changes of the serum levels of bone turnover markers, Dkk-1 and sclerostin are reported in Figure 1. CTX-I, Dkk-1 and sclerostin decreased abruptly after 1 week of treatment with certolizumab pegol (-27% ± 21.5%, -50% ± 13.2% and -30% ± 30.4% respectively), and similar results were found after 4 weeks. Methyl-prednisolone induced comparable changes, albeit less evident, on CTX-I and Wnt inhibitors. We found an increase in PINP serum levels after treatment with anti-TNFα, while we observed a decrease with methyl-prednisolone. Tocilizumab did not significantly affect BTMs or Wnt inhibitors.

Conclusion: TNFα inhibition seems to have a strong and quick effect on BTMs and Wnt inhibitors, which was not observed with IL-6 blockade, at least in the short-term. Glucocorticoid treatment exerts similar, though less prominent, changes, potentially linked to the suppression of inflammation, nonetheless it still show some undesired effects on bone metabolism (ie, suppression of bone formation).

Figure 1. Bone turnover markers and Wnt inhibitors changes after 1 and 4 weeks of treatment with methyl-prednisolone -MPONE-, tocilizumab -TCZ- and certolizumab pegol -CMZ-


Disclosure: A. Fassio, None; G. Adami, None; O. Viapiana, Abiogen; L. Idolazzi, None; G. Orsolini, None; A. Giollo, None; D. Gatti, None; M. Rossini, Abiogen, 5, Biogen, 5, Eli Lilly, 5, 8, Novartis, 5, UCB, 5.

To cite this abstract in AMA style:

Fassio A, Adami G, Viapiana O, Idolazzi L, Orsolini G, Giollo A, Gatti D, Rossini M. Acute Effects of IL-6 Blockade, TNFα Inhibitor or Glucocorticoids on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/acute-effects-of-il-6-blockade-tnf%ce%b1-inhibitor-or-glucocorticoids-on-bone-turnover-markers-and-wnt-inhibitors-in-early-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARP Annual Meeting 2019

ACR Meeting Abstracts - https://acrabstracts.org/abstract/acute-effects-of-il-6-blockade-tnf%ce%b1-inhibitor-or-glucocorticoids-on-bone-turnover-markers-and-wnt-inhibitors-in-early-rheumatoid-arthritis/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology